Assessing and Treating Patients with High-Risk NDMM
Elan Gorshein, DO, JD, MPH, describes potential approaches to managing high-risk patients with transplant-eligible NDMM.
Exploring the GMMG-CONCEPT Study in Patients With Transplant-Eligible NDMM
Noffar Bar, MD, explains the GMMG-CONCEPT trial in patients with transplant-eligible NDMM.
Multiple Myeloma: An Evolving Treatment Landscape
Closing out their discussion on multiple myeloma, expert panelists share expectations and hopes for the future treatment paradigm.
2-Minute Drill: Closing Thoughts on the 2023 ASCO Annual Meeting
Thought leaders from various institutions offered their closing thoughts the 2023 ASCO Annual Meeting.
2-Minute Drill: Shameless Plus From the 2023 ASCO Annual Meeting
Thought leaders from various institutions offered their shameless plug the 2023 ASCO Annual Meeting.
2-Minute Drill: Biggest Winner From the 2023 ASCO Annual Meeting
Thought leaders from various institutions offered their take on the biggest winner that came out of the 2023 ASCO Annual Meeting.
Transplant-Eligible NDMM: Selecting Induction Therapy Based on Risk Status
In the setting of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider how risk status may affect the selection of induction therapy.
Patient Profile 3: A 58-Year-Old with IgG Kappa Multiple Myeloma
Experts present the case of a 58-year-old patient with IgG kappa multiple myeloma and offer their initial impressions.
Key Updates from the GRIFFIN Trial in Multiple Myeloma
Experts on multiple myeloma discuss recent updates from the GRIFFIN trial on patients with transplant-eligible multiple myeloma.
Patient Profile 1: A 45-Year-Old with Transplant-Eligible Multiple Myeloma
A panel of clinical experts presents the case of a patient with high-risk multiple myeloma (MM) who underwent transplant.
Quadruplet Induction Therapy in Patients With Transplant-Eligible NDMM
Shared insight on the advent of quadruplet therapy regimens in the induction setting of transplant-eligible newly diagnosed multiple myeloma.
Treatment Duration and Maintenance Therapy in NDMM
Clinical insights on treatment duration and the decision to place patients with newly diagnosed MM on maintenance therapy.
2-Minute Drill: Trials Needing Follow-Up From the 2023 ASCO Annual Meeting
Thought leaders from various institutions offered their take on the trial the trial they think may need the most follow-up as a next step following the 2023 ASCO Annual Meeting.
Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma
Abdullah Khan, MBBS, explains the current data on bispecific T-cell engaging antibodies for the treatment of relapsed multiple myeloma.
Available Treatment Options for Patients with Relapsed Multiple Myeloma
Ashley Rosko, MD, presents the case of a 72-year-old woman with relapsed multiple myeloma for discussion.
2-Minute Drill: FDA Action-Worthy Trials From the 2023 ASCO Annual Meeting
Thought leaders from various institutions offered their take on the trial they think may lead to the next FDA approval following data that were presented at the 2023 ASCO Annual Meeting.
Tailoring Treatment Approaches for Patients with MDS
An overview of the various treatment options available for patients with MDS, with an emphasis on the importance of tailoring treatment choices based on risk profiles.
MDS Diagnosis and Risk Stratification
James K McCloskey, MD, Jamie L Koprivnikar, MD, and Christina Cho, MD discuss the diagnosis of myelodysplastic syndrome (MDS) and the importance of risk stratification in guiding treatment decisions.
Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics
The panel discusses how they would approach the treatment of a patient with relapsed/refractory MM who progresses on BCMA-targeting bispecifics.
Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives
The panel discusses the approach to step-up and treatment dosing for bispecifics in their respective health care systems.